SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Increase (Decrease) in Accrued Interest Receivable, Net
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Increase (Decrease) in Accrued Interest Receivable, Net of -$14.90 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet · last filed 2026-03-31
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2024-12-31 was -$4.00, a 100.16% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2024-09-30 was -$7.22K, a 231.67% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2024-06-30 was -$4.74K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in accrued interest receivable, net for the quarter ending 2024-03-31 was -$2.94K, a 141.82% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in accrued interest receivable, net for fiscal 2024 was -$14.90K, a 200.00% decline from fiscal 2023.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in accrued interest receivable, net for fiscal 2023 was $14.90K.
| Period end | Increase (Decrease) in Accrued Interest Receivable, Net 3 month | Increase (Decrease) in Accrued Interest Receivable, Net 6 month | Increase (Decrease) in Accrued Interest Receivable, Net 9 month | Increase (Decrease) in Accrued Interest Receivable, Net 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$4.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$7.23K derived: sum of 2 quarters · filed 2026-03-31 | -$11.96K derived: sum of 3 quarters · filed 2026-03-31 | -$14.90K 10-K · filed 2026-03-31 |
| 2024-09-30 | -$7.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$11.96K derived: sum of 2 quarters · filed 2025-11-13 | -$14.90K 10-Q · filed 2025-11-13 | -$12.43K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$4.74K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$7.67K 10-Q · filed 2025-08-13 | -$5.21K derived: sum of 3 quarters · filed 2025-08-13 | $276.00 derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$2.94K 10-Q · filed 2025-05-08 | -$471.00 derived: sum of 2 quarters · filed 2025-05-08 | $5.01K derived: sum of 3 quarters · filed 2025-05-08 | $4.94K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $2.47K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $7.95K derived: sum of 2 quarters · filed 2025-02-26 | $7.88K derived: sum of 3 quarters · filed 2025-02-26 | $14.90K 10-K · filed 2025-02-26 |
| 2023-09-30 | $5.49K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $5.41K derived: sum of 2 quarters · filed 2024-11-13 | $12.44K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$73.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-09-04 | $6.95K 10-Q · filed 2024-09-04 | ||
| 2023-03-31 | $7.02K 10-Q/A · filed 2024-09-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |